Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06061081 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
A Phase 2 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT06061081 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 21 participants.
The verdict
NCT06061081, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
Interventions
- DRUG Placebo
- DRUG VH3739937
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06061081
The ClinicalTrials.gov registry entry for NCT06061081 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06061081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06061081 about?
NCT06061081 is a clinical study titled "A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1". The primary purpose of this study is to assess the antiviral activity of VH3739937 in Human Immunodeficiency Virus Type-1 (HIV-1) infected treatment naive (TN) participants during monotherapy.
What is the current status of trial NCT06061081?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-12-21. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT06061081?
The interventions under investigation include: Placebo (DRUG), VH3739937 (DRUG).
Who is sponsoring clinical trial NCT06061081?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.